According to a recent market research report by Triton Market Research, Asia’s CDX market was valued at $1.4 billion in 2022 and is likely to grow to $3.85 billion by 2030 with a CAGR of 13%.
While CDX growth has already accelerated in the West due to an increased focus on personalized medicine, Asia will experience high CDx growth in the future, too.
The Asian CDX market includes a variety of mechanisms including PCR, NGS, Immunohistochemistry, In-Situ Hybridization, etc. While CDx use in Asia is focused on products for cancer, other indications where CDx products will be used include infectious diseases, neurology, cardiology, etc. With respect to the development of CDx registration regulations, Japan and Australia are the most developed, and China, Taiwan, and Korea CDx regulations are evolving. These three countries currently register CDx products as devices or IVDs.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with business development and regulatory issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.
Source used in the article: https://www.lek.com/sites/default/files/insights/pdf-attachments/2137_Opportunities-Companion-Diagnostics-Asia-Pacific-v2.pdf